3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Oxaliplatin
270
Bevacizumab
260
Fluorouracil
249
Irinotecan
240
Leucovorin
218
Capecitabine
196
Cetuximab
161
Colonoscopy
74
Folfox protocol
70
Panitumumab
64
regorafenib
62
Drug Therapy
52
Radiotherapy
50
HMPL-013
50
Blood Specimen Collection
45
trifluridine tipiracil drug combination
43
pembrolizumab
41
Surveys and Questionnaires
35
Standard of Care
35
Nivolumab
34
Neoadjuvant Therapy
34
Surgical Procedures, Operative
33
Magnetic Resonance Spectroscopy
31
IFL protocol
27
Trifluridine
26
Interviews as Topic
26
Celecoxib
26
XELOX
25
Early Intervention, Educational
24
Specimen Handling
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Colorectal Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled